Consistent with this fundamental role of p75NTR in a broad range of AD pathological cascades, the present clinical trial demonstrated slowing of longitudinal progression of biomarkers of presynaptic, postsynaptic and neuronal integrity (SNAP25, NG and sMRI), synaptic function ([18F]-FDG PET) and glial activation (YKL40). Here, CHI3L1 is linked to Alzheimer disease.